PASW revenueFY2025CN¥34.15M
- FY YoY
- -61.0%
PASW revenue was CN¥34.15M for fiscal 2025 (ended Sep 30, 2025), down 61.0% from fiscal 2024.
Ping An Biomedical Co. Ltd. (PASW) financials
For fiscal 2025 (ended Sep 30, 2025), Ping An Biomedical Co. Ltd. reported CN¥34.15M of revenue and -CN¥12.83M of net income. Figures are in CNY, the currency of its SEC filings.
- Revenue, FY2025
- CN¥34.15M
- Revenue growth, YoY
- -61.0%
- Net income, FY2025
- -CN¥12.83M
- Net margin
- -37.6%
- EPS, diluted, FY2025
- -CN¥0.69
- Cash
- CN¥1.17M
FY2023FY2025
FY2023FY2025
PASW revenue and earnings growth
PASW net incomeFY2025-CN¥12.83M
PASW net income was -CN¥12.83M for fiscal 2025 (ended Sep 30, 2025), compared with -CN¥1.28M in fiscal 2024.
PASW EPSFY2025-CN¥0.69
PASW diluted EPS was -CN¥0.69 for fiscal 2025 (ended Sep 30, 2025), compared with -CN¥0.07 in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 |
|---|---|---|---|
| Revenue | CN¥34.15M | CN¥87.62M | CN¥82.56M |
| Cost of revenue | CN¥33.20M | CN¥82.21M | CN¥78.32M |
| Gross profit | CN¥949.5K | CN¥5.42M | CN¥4.24M |
| Selling, general and admin | CN¥6.01M | CN¥4.99M | CN¥3.27M |
| Operating income | -CN¥14.70M | -CN¥2.0K | CN¥612.5K |
| Interest expense | CN¥307.1K | CN¥705.3K | CN¥1.74M |
| Pre-tax income | -CN¥14.68M | -CN¥682.7K | CN¥41.7K |
| Income tax | CN¥1.86M | -CN¥601.5K | -CN¥1.04M |
| Net income | -CN¥12.83M | -CN¥1.28M | -CN¥993.9K |
| EPS, basic | -CN¥0.69 | -CN¥0.07 | -CN¥0.06 |
| EPS, diluted | -CN¥0.69 | -CN¥0.07 | -CN¥0.06 |
| Diluted shares | 18.5M | 18.0M | 18.0M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 |
|---|---|---|---|
| Cash and equivalents | CN¥1.17M | CN¥130.9K | CN¥591.9K |
| Receivables | CN¥16.93M | CN¥40.44M | - |
| Inventory | CN¥441.9K | CN¥127.3K | - |
| Current assets | CN¥63.70M | CN¥53.31M | - |
| Total assets | CN¥68.41M | CN¥56.85M | - |
| Current liabilities | CN¥23.08M | CN¥63.58M | - |
| Short-term debt | CN¥10.00M | CN¥10.00M | - |
| Total liabilities | CN¥23.17M | CN¥64.04M | - |
| Shareholders' equity | CN¥45.24M | -CN¥7.19M | -CN¥5.86M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 |
|---|---|---|---|
| Operating cash flow | -CN¥6.43M | CN¥14.63M | -CN¥6.08M |
| Investing cash flow | CN¥0 | CN¥15.00M | -CN¥3.37M |
| Financing cash flow | CN¥43.66M | -CN¥30.09M | CN¥8.87M |
| Dividends paid | - | CN¥322.4K | CN¥9.60M |
Key ratios
Source: XBRL data Ping An Biomedical Co. Ltd. files with the SEC, latest filing dated Jan 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
PASW peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PASW | CN¥34.15M | -61.0% | -CN¥12.83M | -37.6% | $4.1M |
| TPR | $8.19B | +13.7% | $1.61B | 19.7% | $26.53B |
| AS | $6.57B | +26.7% | $427.40M | 6.5% | $17.55B |
| LULU | $11.09B | +1.7% | $1.42B | 12.8% | $11.70B |
| LEVI | $6.68B | +6.6% | $589.70M | 8.8% | $8.77B |
| GIL | $3.62B | +10.7% | $398.88M | 11.0% | $6.43B |
| ZGN | €1.92B | -1.5% | €98.58M | 5.1% | $3.77B |
| COLM | $3.43B | +0.1% | $238.77M | 7.0% | $3.61B |
| FIGS | $749.11M | +28.9% | $72.45M | 9.7% | $3.29B |
PASW FAQ
8 questionsWhat is PASW revenue?
Ping An Biomedical Co. Ltd. (PASW) reported CN¥34.15M of revenue for fiscal 2025 (ended Sep 30, 2025). That is down 61.0% from the year before.Is PASW profitable?
No. Ping An Biomedical Co. Ltd. reported a net loss of CN¥12.83M for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does PASW have?
Ping An Biomedical Co. Ltd. reported CN¥1.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is PASW revenue growing?
Ping An Biomedical Co. Ltd.'s revenue changed -61.0% in fiscal 2025, to CN¥34.15M.What is PASW gross margin?
Ping An Biomedical Co. Ltd.'s gross profit was CN¥949.5K on CN¥34.15M of revenue for fiscal 2025 (ended Sep 30, 2025), a gross margin of 2.8%.What is PASW earnings per share?
Diluted earnings per share were -CN¥0.69 for fiscal 2025 (ended Sep 30, 2025), from SEC filings, restated for any stock split those filings show.When did PASW last report financial results?
The latest statements here come from Ping An Biomedical Co. Ltd.'s 20-F filed on Jan 30, 2026, covering the period ended Sep 30, 2025.Where does this PASW financial data come from?
Quantisnow builds these statements from the structured XBRL data Ping An Biomedical Co. Ltd. files with the SEC. It is provided for information only and is not investment advice.